Dare Bioscience Inc (NASDAQ:DARE) Director Roger Hawley bought 454,545 shares of the stock in a transaction on Thursday, April 11th. The shares were bought at an average cost of $1.10 per share, for a total transaction of $499,999.50. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of DARE opened at $1.05 on Tuesday. The company has a market capitalization of $11.99 million, a PE ratio of -0.85 and a beta of 2.35. Dare Bioscience Inc has a 12-month low of $0.60 and a 12-month high of $3.25.
Several equities analysts have recently issued reports on the stock. Maxim Group reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Dare Bioscience in a research note on Thursday, April 4th. ValuEngine raised shares of Dare Bioscience from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd.
An institutional investor recently raised its position in Dare Bioscience stock. Citadel Advisors LLC lifted its holdings in Dare Bioscience Inc (NASDAQ:DARE) by 205.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 106,338 shares of the biotechnology company’s stock after purchasing an additional 71,470 shares during the period. Citadel Advisors LLC owned about 0.93% of Dare Bioscience worth $104,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 6.42% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Dare Bioscience Inc (DARE) Director Roger Hawley Acquires 454,545 Shares” was originally reported by Macon Daily and is the sole property of of Macon Daily. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://macondaily.com/2019/04/16/dare-bioscience-inc-dare-director-roger-hawley-acquires-454545-shares.html.
Dare Bioscience Company Profile
Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.
Further Reading: What are catch-up contributions?
Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.